首页 > 最新文献

Fertility and sterility最新文献

英文 中文
When should assisted reproductive technology workups be performed: following a tiered approach or all on day 1? 应何时进行 ART 检查?是采用分层方法,还是全部在第一天进行?
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.04.035
{"title":"When should assisted reproductive technology workups be performed: following a tiered approach or all on day 1?","authors":"","doi":"10.1016/j.fertnstert.2024.04.035","DOIUrl":"10.1016/j.fertnstert.2024.04.035","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seminal plasma exposure in in vitro fertilization cycles: “Dripping water hollows out stone, not through force but through persistence” 试管婴儿周期中的精浆暴露:"滴水穿石,非力而为"。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.07.016
Qiaosong Han M.D. , Jinwei Hou M.D. , Zhengao Sun M.D., Ph.D.
{"title":"Seminal plasma exposure in in vitro fertilization cycles: “Dripping water hollows out stone, not through force but through persistence”","authors":"Qiaosong Han M.D. , Jinwei Hou M.D. , Zhengao Sun M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.07.016","DOIUrl":"10.1016/j.fertnstert.2024.07.016","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The correlation between menstrual characteristics and fertility in women of reproductive age: a systematic review and meta-analysis 育龄妇女月经特征与生育能力之间的相关性:系统回顾与荟萃分析。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.06.016
<div><h3>Importance</h3><div>Menstruation serves as an indicator of women’s reproductive well-being and plays a pivotal role in their fertility; nevertheless, there remains an ongoing debate regarding the epidemiological evidence linking menstrual characteristics as well as fertility.</div></div><div><h3>Objective</h3><div>To explore the correlation between menstrual characteristics and fertility in women of reproductive age.</div></div><div><h3>Data Sources</h3><div>A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Cochrane libraries to identify research articles published up until February 9, 2024.</div></div><div><h3>Study Selection and Synthesis</h3><div><span>We included all studies in which the relationship between menstrual characteristics and pregnancy rates among women of reproductive age was investigated. We excluded studies involving the administration of </span>oral contraceptives<span>, the application of assisted reproductive technologies, and individuals with a documented history of infertility or partners with a known history of infertility.</span></div></div><div><h3>Main Outcome Measure(s)</h3><div>Clinical pregnancy and miscarriage.</div></div><div><h3>Result(s)</h3><div><span>This meta-analysis was composed of nine studies involving a total of 399,966 women, and the evidential quality derived from these studies was deemed to be high with a low risk of bias. Compared with a normal menstrual cycle<span> length (25–32 days), the impact of a short (<25 days) or long (>32 days) menstrual cycle on a woman’s pregnancy was relatively insignificant ([odds ratio {OR}, 0.81; 95% confidence interval {CI}, 0.65–1.01; I</span></span><sup>2</sup>, 68%]; [OR, 0.89; 95% CI, 0.75–1.06; I<sup>2</sup>, 60%], respectively); however, a change in cycle length may increase the risk of miscarriage ([relative risk, 1.87; 95% CI, 1.11–3.15; I<sup>2</sup>, 0]; [relative risk, 1.66; 95% CI, 1.07, 2.57; I<sup>2</sup><span>, 43%], respectively). In comparison to women experiencing menarche<span> at a typical age (12–14 years), those with a late age at menarche (>14 years) exhibited a decreased likelihood of pregnancy (OR, 0.92; 95% CI, 0.91–0.93; I</span></span><sup>2</sup><span>, 0%); and compared with women experiencing a normal duration of menstrual bleeding<span> (4–7 days), those with a short duration of menstrual bleeding (<4 days) exhibited reduced fertility potential (OR, 0.86; 95% CI, 0.84–0.88; I</span></span><sup>2</sup>, 29%).</div></div><div><h3>Conclusion(s)</h3><div>Short and long menstrual cycle lengths may elevate women’s susceptibility to spontaneous abortion, whereas late age at menarche as well as short duration of menstrual bleeding appear to be linked to diminished fertility among women of reproductive age.</div></div><div><h3>Clinical Trial Registration</h3><div>PROSPERO CRD42023487458 (9 December 2023).</div></div><div><div>La correlación entre las características menstruales y la f
重要性:月经是女性生殖健康的一项指标,对女性的生育率起着关键作用;然而,关于月经特征与生育率之间的流行病学证据仍存在争议:探讨育龄妇女月经特征与生育率之间的相关性:数据来源:我们使用PubMed、Embase、Web of Science和Cochrane图书馆进行了全面的文献检索,以确定截至2024年2月9日发表的研究文章:我们纳入了所有调查育龄妇女月经特征与怀孕率之间关系的研究。我们排除了涉及口服避孕药、应用辅助生殖技术以及有不孕症病史记录的个人或已知有不孕症病史的伴侣的研究:主要结果:临床妊娠和流产:这项荟萃分析由九项研究组成,共涉及 399 966 名女性,这些研究的证据质量较高,偏倚风险较低。与正常月经周期长度(2532 天)相比,月经周期短(32 天)对妇女怀孕的影响相对较小(OR=0.81,CI [0.65,1.01],I2=68%;OR=0.89,CI [0.75,1.06],I2=60%);然而,周期长度的变化可能会增加流产风险(RR=1.87,CI [1.11,3.15],I2=0%;RR=1.66,CI [1.07,2.57],I2=43%)。与月经初潮年龄正常(1214 岁)的女性相比,月经初潮年龄较晚(>14 岁)的女性怀孕的可能性较低(OR=0.92,CI [0.91,0.93],I2=0%);与月经出血持续时间正常(47 天)的女性相比,月经出血持续时间较短的女性怀孕的可能性较低(2=29%):月经周期过短和过长可能会增加女性自然流产的易感性,而月经初潮年龄过晚和月经出血持续时间过短似乎与育龄女性生育能力下降有关。
{"title":"The correlation between menstrual characteristics and fertility in women of reproductive age: a systematic review and meta-analysis","authors":"","doi":"10.1016/j.fertnstert.2024.06.016","DOIUrl":"10.1016/j.fertnstert.2024.06.016","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Importance&lt;/h3&gt;&lt;div&gt;Menstruation serves as an indicator of women’s reproductive well-being and plays a pivotal role in their fertility; nevertheless, there remains an ongoing debate regarding the epidemiological evidence linking menstrual characteristics as well as fertility.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To explore the correlation between menstrual characteristics and fertility in women of reproductive age.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Data Sources&lt;/h3&gt;&lt;div&gt;A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Cochrane libraries to identify research articles published up until February 9, 2024.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Selection and Synthesis&lt;/h3&gt;&lt;div&gt;&lt;span&gt;We included all studies in which the relationship between menstrual characteristics and pregnancy rates among women of reproductive age was investigated. We excluded studies involving the administration of &lt;/span&gt;oral contraceptives&lt;span&gt;, the application of assisted reproductive technologies, and individuals with a documented history of infertility or partners with a known history of infertility.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measure(s)&lt;/h3&gt;&lt;div&gt;Clinical pregnancy and miscarriage.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Result(s)&lt;/h3&gt;&lt;div&gt;&lt;span&gt;This meta-analysis was composed of nine studies involving a total of 399,966 women, and the evidential quality derived from these studies was deemed to be high with a low risk of bias. Compared with a normal menstrual cycle&lt;span&gt; length (25–32 days), the impact of a short (&lt;25 days) or long (&gt;32 days) menstrual cycle on a woman’s pregnancy was relatively insignificant ([odds ratio {OR}, 0.81; 95% confidence interval {CI}, 0.65–1.01; I&lt;/span&gt;&lt;/span&gt;&lt;sup&gt;2&lt;/sup&gt;, 68%]; [OR, 0.89; 95% CI, 0.75–1.06; I&lt;sup&gt;2&lt;/sup&gt;, 60%], respectively); however, a change in cycle length may increase the risk of miscarriage ([relative risk, 1.87; 95% CI, 1.11–3.15; I&lt;sup&gt;2&lt;/sup&gt;, 0]; [relative risk, 1.66; 95% CI, 1.07, 2.57; I&lt;sup&gt;2&lt;/sup&gt;&lt;span&gt;, 43%], respectively). In comparison to women experiencing menarche&lt;span&gt; at a typical age (12–14 years), those with a late age at menarche (&gt;14 years) exhibited a decreased likelihood of pregnancy (OR, 0.92; 95% CI, 0.91–0.93; I&lt;/span&gt;&lt;/span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;span&gt;, 0%); and compared with women experiencing a normal duration of menstrual bleeding&lt;span&gt; (4–7 days), those with a short duration of menstrual bleeding (&lt;4 days) exhibited reduced fertility potential (OR, 0.86; 95% CI, 0.84–0.88; I&lt;/span&gt;&lt;/span&gt;&lt;sup&gt;2&lt;/sup&gt;, 29%).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion(s)&lt;/h3&gt;&lt;div&gt;Short and long menstrual cycle lengths may elevate women’s susceptibility to spontaneous abortion, whereas late age at menarche as well as short duration of menstrual bleeding appear to be linked to diminished fertility among women of reproductive age.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical Trial Registration&lt;/h3&gt;&lt;div&gt;PROSPERO CRD42023487458 (9 December 2023).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;La correlación entre las características menstruales y la f","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply of the authors: Seminal plasma exposure in IVF cycles: “dripping water hollows out stone, not through force but through persistence” 回应:试管婴儿周期中的精浆暴露:"滴水穿石,非力而为"。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.08.344
Susanne Liffner M.D., Ph.D., Gunilla Sydsjö Ph.D., Elizabeth Nedstrand M.D., Ph.D.
{"title":"Reply of the authors: Seminal plasma exposure in IVF cycles: “dripping water hollows out stone, not through force but through persistence”","authors":"Susanne Liffner M.D., Ph.D.,&nbsp;Gunilla Sydsjö Ph.D.,&nbsp;Elizabeth Nedstrand M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.08.344","DOIUrl":"10.1016/j.fertnstert.2024.08.344","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic donor insemination for LGBTQ+ families: a systematic review 针对 LGBTQ+ 家庭的治疗性人工授精:系统性综述。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.08.347
Liam Kali B.A., C.M

Importance

Lesbian, gay, bisexual, transgender, and queer+ (LGBTQ+) families deserve evidence-based care within environments designed for their unique needs; however, care provided in fertility clinics has been reported to fall short, most notably for assigned female at birth recipients of therapeutic donor insemination (TDI).

Objective

To identify the aspects of routine infertility care that are clinically appropriate for this unique patient population, specifically those seeking pregnancy with donor sperm. The research question was posed, “What screening and treatment protocols are supported by the evidence regarding TDI care for LGBTQ+ families?”

Evidence Review

High quality, prospective studies specific to and/or inclusive of this patient population in assisted reproductive care contexts is limited, however evidence regarding age-informed prognosis, screening guidelines, treatment outcomes, insemination timing, number of inseminations per cycle, when to refer, and safety of the procedure were found.

Findings

Findings indicate that compared with routine infertility care protocols, a low-tech, low-intervention model of care for ovulatory LGBTQ+ individuals renders equal or higher success rates without increasing risk.

Conclusion

Given the current evidence, TDI for LGBTQ+ families can, with support and training, be provided appropriately in a variety of contexts, including community-based and primary care settings as well as in fertility clinics.

Relevance

This review establishes the current state of the evidence supporting TDI for LGBTQ+ families, expanding access to care for recipients as well as their care providers and outlining areas for further study.
重要性:女同性恋、男同性恋、双性恋、跨性别者和同性恋+(LGBTQ+)家庭应该在为满足其独特需求而设计的环境中获得循证医疗服务;然而,据报道,不孕不育诊所提供的医疗服务并不完善,尤其是对于接受治疗性供精人工授精(TDI)的出生时即被指定为女性的患者:目的:确定常规不孕不育护理中哪些方面适合这一特殊患者群体,特别是那些希望通过捐献精子怀孕的患者。提出的研究问题是:"关于LGBTQ+家庭的TDI护理,哪些筛查和治疗方案得到了证据的支持?针对和/或在辅助生殖治疗中包括这一患者群体的高质量前瞻性研究有限,但我们发现了有关年龄预后、筛查指南、治疗结果、人工授精时机、每个周期人工授精次数、何时转诊以及手术安全性等方面的证据:研究结果表明,与常规不孕不育治疗方案相比,针对不排卵的 LGBTQ+ 人士的低技术、低干预治疗模式具有相同或更高的成功率,且不会增加风险:鉴于目前的证据,LGBTQ+家庭在获得支持和培训的情况下,可以在各种环境下(包括社区和初级医疗机构以及不孕不育诊所)提供适当的TDI:本综述确定了支持为 LGBTQ+ 家庭提供 TDI 的现有证据,扩大了受助者及其护理提供者获得护理的机会,并概述了有待进一步研究的领域。
{"title":"Therapeutic donor insemination for LGBTQ+ families: a systematic review","authors":"Liam Kali B.A., C.M","doi":"10.1016/j.fertnstert.2024.08.347","DOIUrl":"10.1016/j.fertnstert.2024.08.347","url":null,"abstract":"<div><h3>Importance</h3><div>Lesbian, gay, bisexual, transgender, and queer+ (LGBTQ+) families deserve evidence-based care within environments designed for their unique needs; however, care provided in fertility clinics has been reported to fall short, most notably for assigned female at birth recipients of therapeutic donor insemination (TDI).</div></div><div><h3>Objective</h3><div>To identify the aspects of routine infertility care that are clinically appropriate for this unique patient population, specifically those seeking pregnancy with donor sperm. The research question was posed, “What screening and treatment protocols are supported by the evidence regarding TDI care for LGBTQ+ families?”</div></div><div><h3>Evidence Review</h3><div>High quality, prospective studies specific to and/or inclusive of this patient population in assisted reproductive care contexts is limited, however evidence regarding age-informed prognosis, screening guidelines, treatment outcomes, insemination timing, number of inseminations per cycle, when to refer, and safety of the procedure were found.</div></div><div><h3>Findings</h3><div>Findings indicate that compared with routine infertility care protocols, a low-tech, low-intervention model of care for ovulatory LGBTQ+ individuals renders equal or higher success rates without increasing risk.</div></div><div><h3>Conclusion</h3><div>Given the current evidence, TDI for LGBTQ+ families can, with support and training, be provided appropriately in a variety of contexts, including community-based and primary care settings as well as in fertility clinics.</div></div><div><h3>Relevance</h3><div>This review establishes the current state of the evidence supporting TDI for LGBTQ+ families, expanding access to care for recipients as well as their care providers and outlining areas for further study.</div></div>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fresh or frozen oocyte donation: is there a bad egg? 新鲜或冷冻卵母细胞捐赠:有坏卵子吗?
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.08.338
Luce A. Kassi M.D., Jennifer L. Eaton M.D., M.S.C.I.
{"title":"Fresh or frozen oocyte donation: is there a bad egg?","authors":"Luce A. Kassi M.D.,&nbsp;Jennifer L. Eaton M.D., M.S.C.I.","doi":"10.1016/j.fertnstert.2024.08.338","DOIUrl":"10.1016/j.fertnstert.2024.08.338","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial and socioeconomic disparities in fertility treatment provision for patients with polycystic ovary syndrome 为多囊卵巢综合征患者提供生育治疗的种族和社会经济差异。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.06.014
<div><h3>Objective</h3><div>To assess whether the provision of fertility treatment for patients with polycystic ovary syndrome (PCOS) varies by patient and physician-level demographic characteristics.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Setting</h3><div>University health system.</div></div><div><h3>Patient(s)</h3><div>Patients seeking care for PCOS and infertility from 2007–2021.</div></div><div><h3>Intervention(s)</h3><div>Patient age, body mass index, race, ethnicity, estimated household income, primary insurance payor, provider sex, and provider medical specialty.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Prescriptions for fertility treatment, including clomiphene citrate (CC), letrozole, and injectable gonadotropins. Differences in patient and physician demographics between patients who did as well as did not receive a prescription were identified with univariable analysis. Multilevel mixed-effects logistic regression was performed to determine associations between patient and physician demographics and prescription receipt.</div></div><div><h3>Result(s)</h3><div>A total of 3,435 patients with PCOS and infertility were identified, with a mean age of 31.1 ± 5.7 years. Of the 68.8% of patients who received a prescription, 47.8% of prescriptions were CC, 38.6% were letrozole, and 13.7% were injectable gonadotropins. There were lower odds of prescription receipt for Black patients compared with White patients (adjusted odds ratio [aOR], 0.75; 95% confidence interval [CI], 0.61–0.93), those with estimated household income below the federal poverty level compared with those above the national median (aOR, 0.71; 95% CI, 0.46–0.97), and those with public compared with commercial insurance (aOR, 0.53; 95% CI, 0.40–0.71). These disparities persisted in a subanalysis of patients prescribed oral medications only with lower odds of prescription receipt for Black compared with White patients (aOR, 0.74; 95% CI, 0.57–0.95), those with estimated household income below the federal poverty level compared with above the national median (aOR, 0.93; 95% CI, 0.87–0.98), and those with public compared with commercial insurance (aOR, 0.57; 95% CI, 0.42–0.76). Black patients waited, on average, 153.3 days longer than White patients, from the initial visit to the prescription receipt. Patients had lower odds of receiving any prescription from family medicine physicians (aOR, 0.36; 95% CI, 0.24–0.52) and general internal medicine physicians (aOR, 0.55; 95% CI, 0.42–0.73) compared with reproductive endocrinologists.</div></div><div><h3>Conclusion(s)</h3><div>Racial and socioeconomic disparities exist in the provision of infertility treatments for patients with PCOS. Fewer primary care physicians engaged in first-line fertility treatment, indicating an opportunity for physician education to improve access to fertility care.</div></div><div><div>Diferencias raciales y socioeconómicas en la prestación de tratamient
目的评估为多囊卵巢综合征(PCOS)患者提供的生育治疗是否因患者和医生的人口统计学特征而异:设计:回顾性队列研究:2007-2021年间在某大学医疗系统就诊的多囊卵巢综合征和不孕症患者:主要结果测量指标:生育治疗处方,包括枸橼酸氯米芬、来曲唑和注射用促性腺激素。通过单变量分析确定了开具处方与未开具处方的患者和医生在人口统计学方面的差异。为了确定患者和医生的人口统计学特征与接受处方之间的关系,进行了多层次混合效应逻辑回归:共发现 3435 名多囊卵巢综合征和不孕症患者,平均年龄为 31.1 +/- 5.7 岁。在68.8%收到处方的患者中,47.8%的处方为枸橼酸克罗米芬,38.6%为来曲唑,13.7%为注射用促性腺激素。黑人患者与白人患者相比(aOR 0.75,95% CI 0.61-0.93),估计家庭收入低于联邦贫困线(FPL)与高于全国中位数相比(aOR 0.71,95% CI 0.46-0.97),以及公共保险与商业保险相比(aOR 0.53,95% CI 0.40-0.71),接受处方的几率都较低。在一项仅针对口服药物处方患者的子分析中,这些差异依然存在:黑人患者获得处方的几率低于白人患者(aOR 0.74,95% CI 0.57-0.95);估计家庭收入低于 FPL 而高于全国中位数(aOR 0.93,95% CI 0.87-0.98);以及公共保险患者低于商业保险患者(aOR 0.57,95% CI 0.42-0.76)。黑人患者从初次就诊到拿到处方的平均时间比白人患者长 153.3 天。与生殖内分泌科医生相比,患者从家庭医生(aOR 0.36,95% CI 0.24-0.52)和普通内科医生(aOR 0.55,95% CI 0.42-0.73)处获得处方的几率较低:结论:在为多囊卵巢综合征患者提供不孕不育治疗方面存在种族和社会经济差异。参与一线不孕不育治疗的初级保健医生较少,这表明医生有机会通过教育来改善不孕不育治疗的可及性。
{"title":"Racial and socioeconomic disparities in fertility treatment provision for patients with polycystic ovary syndrome","authors":"","doi":"10.1016/j.fertnstert.2024.06.014","DOIUrl":"10.1016/j.fertnstert.2024.06.014","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To assess whether the provision of fertility treatment for patients with polycystic ovary syndrome (PCOS) varies by patient and physician-level demographic characteristics.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Retrospective cohort study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting&lt;/h3&gt;&lt;div&gt;University health system.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patient(s)&lt;/h3&gt;&lt;div&gt;Patients seeking care for PCOS and infertility from 2007–2021.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Intervention(s)&lt;/h3&gt;&lt;div&gt;Patient age, body mass index, race, ethnicity, estimated household income, primary insurance payor, provider sex, and provider medical specialty.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measure(s)&lt;/h3&gt;&lt;div&gt;Prescriptions for fertility treatment, including clomiphene citrate (CC), letrozole, and injectable gonadotropins. Differences in patient and physician demographics between patients who did as well as did not receive a prescription were identified with univariable analysis. Multilevel mixed-effects logistic regression was performed to determine associations between patient and physician demographics and prescription receipt.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Result(s)&lt;/h3&gt;&lt;div&gt;A total of 3,435 patients with PCOS and infertility were identified, with a mean age of 31.1 ± 5.7 years. Of the 68.8% of patients who received a prescription, 47.8% of prescriptions were CC, 38.6% were letrozole, and 13.7% were injectable gonadotropins. There were lower odds of prescription receipt for Black patients compared with White patients (adjusted odds ratio [aOR], 0.75; 95% confidence interval [CI], 0.61–0.93), those with estimated household income below the federal poverty level compared with those above the national median (aOR, 0.71; 95% CI, 0.46–0.97), and those with public compared with commercial insurance (aOR, 0.53; 95% CI, 0.40–0.71). These disparities persisted in a subanalysis of patients prescribed oral medications only with lower odds of prescription receipt for Black compared with White patients (aOR, 0.74; 95% CI, 0.57–0.95), those with estimated household income below the federal poverty level compared with above the national median (aOR, 0.93; 95% CI, 0.87–0.98), and those with public compared with commercial insurance (aOR, 0.57; 95% CI, 0.42–0.76). Black patients waited, on average, 153.3 days longer than White patients, from the initial visit to the prescription receipt. Patients had lower odds of receiving any prescription from family medicine physicians (aOR, 0.36; 95% CI, 0.24–0.52) and general internal medicine physicians (aOR, 0.55; 95% CI, 0.42–0.73) compared with reproductive endocrinologists.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion(s)&lt;/h3&gt;&lt;div&gt;Racial and socioeconomic disparities exist in the provision of infertility treatments for patients with PCOS. Fewer primary care physicians engaged in first-line fertility treatment, indicating an opportunity for physician education to improve access to fertility care.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Diferencias raciales y socioeconómicas en la prestación de tratamient","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Committee for Monitoring Assisted Reproductive Technology world report: assisted reproductive technology, 2015 and 2016 国际辅助生殖技术监测委员会世界报告:2015 年和 2016 年辅助生殖技术。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.07.009
<div><h3>Objective</h3><div>To report utilization, effectiveness, and safety of assisted reproductive technologies in 2015 and 2016.</div></div><div><h3>Design</h3><div>A retrospective, cross-sectional survey of 3,103 assisted reproductive technology clinics in 74 countries in 2015 and 3,249 clinics in 79 countries in 2016 that submitted cycle and pregnancy outcome data through national and regional registries.</div></div><div><h3>Setting</h3><div>Seventy-nine countries and >3,000 assisted reproductive technology clinics.</div></div><div><h3>Patient(s)</h3><div>Patients undergoing assisted reproductive technology procedures.</div></div><div><h3>Intervention(s)</h3><div>Assisted reproductive technology.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Outcomes on country, regional, and global levels.</div></div><div><h3>Result(s)</h3><div>Reported for 2015: 2,358,239 cycles with 548,652 infants born; for 2016: 2,807,963 cycles with 647,188 infants born. Estimated in 2015, ≥2,683,677 cycles resulted in >675,134 infants; in 2016, ≥3,100,448 cycles resulted in ≥723,026 infants. Reported cycles represent approximately 80% of global utilization. In 2015 and 2016, 27.6% and 27.8%, respectively, of women undergoing fresh autologous treatment cycles were aged ≥40 years. Frozen-thawed embryo transfer (ET) cycles accounted for 47.0% and 51.9%, respectively, of all ETs in 2015 and 2016. Oocyte donation cycles accounted for 6.7% and 7.1% of all ETs in 2015 and 2016. Intracytoplasmic sperm injection was performed in 57.7% and 56.4% of autologous aspiration cycles in 2015 and 2016, respectively. The cumulative delivery rate per aspiration cycle for fresh and frozen-thawed ET was 32.4% in 2015 and 33.1% in 2016, respectively. The average number of transferred embryos was 1.70 in 2015 and 1.69 in 2016. The proportion of single ETs in fresh autologous cycles increased from 42.1% in 2015 to 44.0% in 2016. The twin delivery rate decreased from 16.0% in 2015 to 14.7% in 2016, and the triplet rate decreased from 0.6% in 2015 to 0.4% in 2016. The proportion of single ETs in frozen-thawed ET autologous treatment cycles was 62.2% in 2015 and 64.2% in 2016, with twin and triplet rates of 10.1% and 0.3% in 2015 and 10.0% and 0.2% in 2016, respectively.</div></div><div><h3>Conclusion(s)</h3><div>Utilization of assisted reproductive technology treatment and births per cycle increased from 2015 to 2016, although multiple births were reduced. An increasing proportion of frozen-thawed ET cycles, continuing wide variation in use of intracytoplasmic sperm injection, and an increase in single ET rates are reported.</div></div><div><div>Informe mundial del Comité Internacional para el Seguimiento de la Tecnología de Reproducción Asistida: tecnología de la reproducción asistida, 2015 y 2016</div></div><div><h3>Objetivo</h3><div>Informar sobre la utilización, eficacia y seguridad de las tecnologías de reproducción asistida en 2015 y 2016.</div></div><div><h3>Diseño</h3><div
目标:报告 2015 年和 2016 年辅助生殖技术的使用情况、有效性和安全性:报告 2015 年和 2016 年辅助生殖技术的使用情况、有效性和安全性:设计:对2015年74个国家的3103家辅助生殖技术诊所和2016年79个国家的3249家诊所进行回顾性横断面调查,这些诊所通过国家和地区登记处提交了周期和妊娠结果数据:接受辅助生殖技术治疗的患者:辅助生殖技术:主要结果测量:国家、地区和全球层面的结果:2015 年报告:2,358,239 个周期,548,652 名婴儿出生;2016 年报告:2,807,963 个周期,647,188 名婴儿出生。据估计,2015 年,≥2,683,677 个周期,>675,134 名婴儿出生;2016 年,≥3,100,448 个周期,≥723,026 名婴儿出生。报告的周期约占全球使用量的 80%。2015年和2016年,接受新鲜自体周期的女性中,年龄≥40岁的分别占27.6%和27.8%。2015年和2016年,冷冻解冻胚胎移植周期分别占所有胚胎移植的47.0%和51.9%。卵母细胞捐献周期分别占2015年和2016年所有胚胎移植的6.7%和7.1%。2015年和2016年,分别有57.7%和56.4%的自体抽吸周期进行了卵胞浆内单精子注射。2015年和2016年,新鲜胚胎移植和冻融胚胎移植每个抽吸周期的累计分娩率分别为32.4%和33.1%。2015 年和 2016 年移植胚胎的平均数量分别为 1.70 个和 1.69 个。新鲜自体周期的单胚胎移植比例从2015年的42.1%增至2016年的44.0%。双胎分娩率从2015年的16.0%降至2016年的14.7%,三胎分娩率从2015年的0.6%降至2016年的0.4%。冻融胚胎移植自体周期中单胚胎移植比例2015年为62.2%,2016年为64.2%,双胎率和三胎率2015年分别为10.1%和0.3%,2016年分别为10.0%和0.2%.结论:从2015年到2016年,辅助生殖技术的使用率和每个周期的出生率都有所上升,而多胎出生率则有所下降。据报道,冷冻-解冻胚胎移植周期的比例不断增加,卵胞浆内单精子注射的使用情况继续存在较大差异,单胚胎移植率有所上升。
{"title":"International Committee for Monitoring Assisted Reproductive Technology world report: assisted reproductive technology, 2015 and 2016","authors":"","doi":"10.1016/j.fertnstert.2024.07.009","DOIUrl":"10.1016/j.fertnstert.2024.07.009","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To report utilization, effectiveness, and safety of assisted reproductive technologies in 2015 and 2016.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;A retrospective, cross-sectional survey of 3,103 assisted reproductive technology clinics in 74 countries in 2015 and 3,249 clinics in 79 countries in 2016 that submitted cycle and pregnancy outcome data through national and regional registries.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting&lt;/h3&gt;&lt;div&gt;Seventy-nine countries and &gt;3,000 assisted reproductive technology clinics.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patient(s)&lt;/h3&gt;&lt;div&gt;Patients undergoing assisted reproductive technology procedures.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Intervention(s)&lt;/h3&gt;&lt;div&gt;Assisted reproductive technology.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measure(s)&lt;/h3&gt;&lt;div&gt;Outcomes on country, regional, and global levels.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Result(s)&lt;/h3&gt;&lt;div&gt;Reported for 2015: 2,358,239 cycles with 548,652 infants born; for 2016: 2,807,963 cycles with 647,188 infants born. Estimated in 2015, ≥2,683,677 cycles resulted in &gt;675,134 infants; in 2016, ≥3,100,448 cycles resulted in ≥723,026 infants. Reported cycles represent approximately 80% of global utilization. In 2015 and 2016, 27.6% and 27.8%, respectively, of women undergoing fresh autologous treatment cycles were aged ≥40 years. Frozen-thawed embryo transfer (ET) cycles accounted for 47.0% and 51.9%, respectively, of all ETs in 2015 and 2016. Oocyte donation cycles accounted for 6.7% and 7.1% of all ETs in 2015 and 2016. Intracytoplasmic sperm injection was performed in 57.7% and 56.4% of autologous aspiration cycles in 2015 and 2016, respectively. The cumulative delivery rate per aspiration cycle for fresh and frozen-thawed ET was 32.4% in 2015 and 33.1% in 2016, respectively. The average number of transferred embryos was 1.70 in 2015 and 1.69 in 2016. The proportion of single ETs in fresh autologous cycles increased from 42.1% in 2015 to 44.0% in 2016. The twin delivery rate decreased from 16.0% in 2015 to 14.7% in 2016, and the triplet rate decreased from 0.6% in 2015 to 0.4% in 2016. The proportion of single ETs in frozen-thawed ET autologous treatment cycles was 62.2% in 2015 and 64.2% in 2016, with twin and triplet rates of 10.1% and 0.3% in 2015 and 10.0% and 0.2% in 2016, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion(s)&lt;/h3&gt;&lt;div&gt;Utilization of assisted reproductive technology treatment and births per cycle increased from 2015 to 2016, although multiple births were reduced. An increasing proportion of frozen-thawed ET cycles, continuing wide variation in use of intracytoplasmic sperm injection, and an increase in single ET rates are reported.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Informe mundial del Comité Internacional para el Seguimiento de la Tecnología de Reproducción Asistida: tecnología de la reproducción asistida, 2015 y 2016&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objetivo&lt;/h3&gt;&lt;div&gt;Informar sobre la utilización, eficacia y seguridad de las tecnologías de reproducción asistida en 2015 y 2016.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Diseño&lt;/h3&gt;&lt;div","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply of the authors: a commentary on: “Association of serum uric acid with women’s ovarian reserve: observational study and Mendelian randomization analyses” 作者的答复:评述:血清尿酸与女性卵巢储备功能的关系:观察性研究和孟德尔随机分析 "的评论。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.07.494
Guiquan Wang M.D. , Haiyan Yang M.D. , Xintong Jiang M.D. , Weian Mao M.D. , Ping Li M.D. , Xiaojing Lin M.D. , Yan Li M.D. , Zhenhong Ye M.D. , Yurong Zhang M.D. , Wei Chen M.D. , Shuai Yuan M.Med.Sc. , Yue Zhao Ph.D. , Liangshan Mu M.D. Ph.D
{"title":"Reply of the authors: a commentary on: “Association of serum uric acid with women’s ovarian reserve: observational study and Mendelian randomization analyses”","authors":"Guiquan Wang M.D. ,&nbsp;Haiyan Yang M.D. ,&nbsp;Xintong Jiang M.D. ,&nbsp;Weian Mao M.D. ,&nbsp;Ping Li M.D. ,&nbsp;Xiaojing Lin M.D. ,&nbsp;Yan Li M.D. ,&nbsp;Zhenhong Ye M.D. ,&nbsp;Yurong Zhang M.D. ,&nbsp;Wei Chen M.D. ,&nbsp;Shuai Yuan M.Med.Sc. ,&nbsp;Yue Zhao Ph.D. ,&nbsp;Liangshan Mu M.D. Ph.D","doi":"10.1016/j.fertnstert.2024.07.494","DOIUrl":"10.1016/j.fertnstert.2024.07.494","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study 雌四醇(E4)15 毫克/屈螺酮(DRSP)3 毫克联合循环疗法治疗子宫内膜异位症相关疼痛和客观妇科检查结果的有效性和安全性:一项多中心、安慰剂对照、双盲、随机研究。
IF 6.6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.fertnstert.2024.07.011
Tasuku Harada M.D., Ph.D. , Takao Kobayashi M.D., Ph.D. , Akihiro Hirakawa Ph.D. , Toshiaki Takayanagi B.M.L.S. , Masayoshi Nogami M.Sc. , Takayuki Mochiyama M.Pharm. , Masashi Hirayama M.Pharm. , Jean-Michel Foidart M.D., Ph.D. , Yutaka Osuga M.D., Ph.D.
<div><h3>Objective</h3><div>To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis.</div></div><div><h3>Design</h3><div>A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.</div></div><div><h3>Setting</h3><div>Twenty-five study centers in Japan.</div></div><div><h3>Patient(s)</h3><div>A total of 162 Japanese women diagnosed with endometriosis.</div></div><div><h3>Intervention(s)</h3><div>Participants were randomly allocated to the E4/DRSP group or the placebo group. In the E4/DRSP group, participants were orally administered one tablet containing E4 (15 mg) and DRSP (3 mg) daily for 24 days, followed by one placebo tablet for 4 days for a hormone-free interval, constituting a 1-cycle regimen. One placebo tablet was administered once daily for 28 days to participants in the placebo group. The treatments were continued for six cycles (24 weeks) throughout the confirmatory period.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Changes in visual analogue scale (VAS) scores for the most severe pelvic pain (lower abdominal and back pain) from baseline to six treatment cycles at the end of the confirmatory study period.</div></div><div><h3>Result(s)</h3><div>Estetrol/drospirenone showed changes in the mean VAS scores for the most severe pelvic pain (−33.2 mm) from baseline to the end of the 6-cycle treatment. The between-group difference was significant (−8.5 mm; 2-sided 95% confidence interval, −16.1 to −0.9 mm), showing superiority to placebo. The responder rates, ≥30% and ≥50% reductions in the VAS scores from baseline, were higher in the E4/DRSP group than in the placebo group: 53.2% vs. 29.6% and 36.4% vs. 12.3%. Objective gynecological findings (induration of the cul-de-sac, pelvic tenderness, and limited uterine mobility) were significantly improved by E4/DRSP treatment, and the proportions of stable and worsened participants were significantly lower than in the placebo group. Estetrol/drospirenone decreased the size of endometriomas and improved quality of life, on the basis of quality of life–related questionnaires and global impression scores. No safety concerns were observed with E4/DRSP treatment. Few differences were observed in the proportion of participants with hemostasis parameters outside the reference range between the E4/DRSP and placebo groups.</div></div><div><h3>Conclusion(s)</h3><div>Estetrol/drospirenone effectively treats endometriosis-associated pain and improves gynecological findings. Estetrol/drospirenone may be a safe, new option for endometriosis treatment with a potentially decreased risk of thromboembolic events.</div></div><div><h3>Clinical Trial Registration Number</h3><div>jRCT2011210027.</div></div><div><div>Eficacia y seguridad de la combinación de estetrol 15 mg/drospirenona 3 mg en un régimen cíclico para el tratamiento del dolor asociado a la endometriosis y halla
目的评估对日本子宫内膜异位症患者周期性服用雌四醇(E4)15 毫克/屈螺酮(DRSP)3 毫克 24 周的疗效和安全性:设计:一项为期24周的多中心、随机、双盲、安慰剂对照、平行组研究:干预措施:参与者被随机分配到 E4/DRSP 组或安慰剂组。在E4/DRSP组,参与者每天口服一片含E4 15毫克和DRSP 3毫克的药片,连续服用24天,然后在无激素间歇期口服一片安慰剂,连续服用4天,构成一个周期的治疗方案。安慰剂组的参与者每天服用一片安慰剂,连续服用 28 天。在整个确认期,治疗持续6个周期(24周):最严重盆腔疼痛(下腹部和背部疼痛)的视觉模拟量表评分从基线到确证研究期结束时六个治疗周期的变化:E4/DRSP显示,从基线到六个治疗周期结束时,最严重盆腔疼痛的平均视觉模拟评分(-33.2毫米)发生了变化。组间差异显著(-8.5 毫米,双侧 95% 置信区间:-16.1 至-0.9 毫米),显示优于安慰剂(p=0.028)。与安慰剂组相比,E4/DRSP 组的应答率(视觉模拟量表评分比基线降低≥30% 和≥50%)更高:分别为 53.2% 对 29.6% (p=0.004) 和 36.4% 对 12.3% (p结论:E4/DRSP 可有效治疗末期糖尿病:E4/DRSP能有效治疗子宫内膜异位症相关疼痛并改善妇科检查结果。E4/DRSP可能是治疗子宫内膜异位症的安全新选择,并有可能降低血栓栓塞事件的风险。
{"title":"Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study","authors":"Tasuku Harada M.D., Ph.D. ,&nbsp;Takao Kobayashi M.D., Ph.D. ,&nbsp;Akihiro Hirakawa Ph.D. ,&nbsp;Toshiaki Takayanagi B.M.L.S. ,&nbsp;Masayoshi Nogami M.Sc. ,&nbsp;Takayuki Mochiyama M.Pharm. ,&nbsp;Masashi Hirayama M.Pharm. ,&nbsp;Jean-Michel Foidart M.D., Ph.D. ,&nbsp;Yutaka Osuga M.D., Ph.D.","doi":"10.1016/j.fertnstert.2024.07.011","DOIUrl":"10.1016/j.fertnstert.2024.07.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting&lt;/h3&gt;&lt;div&gt;Twenty-five study centers in Japan.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patient(s)&lt;/h3&gt;&lt;div&gt;A total of 162 Japanese women diagnosed with endometriosis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Intervention(s)&lt;/h3&gt;&lt;div&gt;Participants were randomly allocated to the E4/DRSP group or the placebo group. In the E4/DRSP group, participants were orally administered one tablet containing E4 (15 mg) and DRSP (3 mg) daily for 24 days, followed by one placebo tablet for 4 days for a hormone-free interval, constituting a 1-cycle regimen. One placebo tablet was administered once daily for 28 days to participants in the placebo group. The treatments were continued for six cycles (24 weeks) throughout the confirmatory period.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measure(s)&lt;/h3&gt;&lt;div&gt;Changes in visual analogue scale (VAS) scores for the most severe pelvic pain (lower abdominal and back pain) from baseline to six treatment cycles at the end of the confirmatory study period.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Result(s)&lt;/h3&gt;&lt;div&gt;Estetrol/drospirenone showed changes in the mean VAS scores for the most severe pelvic pain (−33.2 mm) from baseline to the end of the 6-cycle treatment. The between-group difference was significant (−8.5 mm; 2-sided 95% confidence interval, −16.1 to −0.9 mm), showing superiority to placebo. The responder rates, ≥30% and ≥50% reductions in the VAS scores from baseline, were higher in the E4/DRSP group than in the placebo group: 53.2% vs. 29.6% and 36.4% vs. 12.3%. Objective gynecological findings (induration of the cul-de-sac, pelvic tenderness, and limited uterine mobility) were significantly improved by E4/DRSP treatment, and the proportions of stable and worsened participants were significantly lower than in the placebo group. Estetrol/drospirenone decreased the size of endometriomas and improved quality of life, on the basis of quality of life–related questionnaires and global impression scores. No safety concerns were observed with E4/DRSP treatment. Few differences were observed in the proportion of participants with hemostasis parameters outside the reference range between the E4/DRSP and placebo groups.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion(s)&lt;/h3&gt;&lt;div&gt;Estetrol/drospirenone effectively treats endometriosis-associated pain and improves gynecological findings. Estetrol/drospirenone may be a safe, new option for endometriosis treatment with a potentially decreased risk of thromboembolic events.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical Trial Registration Number&lt;/h3&gt;&lt;div&gt;jRCT2011210027.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Eficacia y seguridad de la combinación de estetrol 15 mg/drospirenona 3 mg en un régimen cíclico para el tratamiento del dolor asociado a la endometriosis y halla","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":null,"pages":null},"PeriodicalIF":6.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Fertility and sterility
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1